Cooley Advises Depomed in its $240 Million Diabetes Drug Sale to PDL BioPharma
Palo Alto, Calif. – October 22, 2013 – Cooley LLP announced today that it advised Depomed, Inc. in its sale of interests in royalty and milestone payments in the Type 2 diabetes therapeutic area to PDL BioPharma, Inc. for $240.5 million. Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.
The Cooley team advising Depomed on the sale was led by partners Mischi a Marca and Glen Sato and included partner and head of the firm's medical device practice Mark Weeks; partner Bill Morrow (tax); partners Francis Fryscak and Howard Morse (antitrust); special counsel Marina Remennik; and associates Jason Savich and Rena Kaminsky.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors and established companies. Clients partner with Cooley on transformative deals, complex IP matters and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 700 lawyers across eleven offices in the United States and China.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.